Australian Public Assessment Report for ocriplasmin

The absolute difference between the two treatment groups indicates that the NNT is 10 patients. In Study TG-MV-007, the key secondary efficacy endpoint of total PVD was achieved in 10.6% (26/245) of patients in the ocriplasmin 125 µg group and 0% (0/81) of patients in the placebo group (difference 10.6% [95% CI: 6.8, 14.5]; p ................
................